Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
5 B* n, x3 h% r! z' a* I9 |NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
# t" s% F4 [; `, S: o+ Author Affiliations3 K0 a- b. D! W# t5 a. A
V( j( A) `5 \" M% ~5 g+ x
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan # q* |/ h# ^% O4 m- c& p9 R
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " I! _2 \( z) p3 I& h* ~
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
7 B6 B1 f+ n, A$ U2 v4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 3 a/ @1 z* _( ~6 B# S
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 0 H& o$ V9 ?7 @6 ^* d. B+ r1 C2 ]
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ( U: O7 | M b2 P7 t% O
7Kinki University School of Medicine, Osaka 589-8511, Japan " e) m1 L- Q4 x, w' X6 L
8Izumi Municipal Hospital, Osaka 594-0071, Japan
; K$ `3 V+ e% A6 |3 `4 e9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
# u) z& P4 a/ k3 I( O# p dCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
8 L( Q6 ~, S3 ^, k/ tAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
, S6 A7 U9 m& E/ t3 W; o% x1 E6 b+ I% l- t0 d
|